Fig. 2From: Suppression of lung cancer progression by isoliquiritigenin through its metabolite 2, 4, 2’, 4’-TetrahydroxychalconeISL abolishes serum-induced actin reorganization and focal adhesion assembly. H1299 (a) and A549 cells (b) were treated with vehicle or 10 μM ISL for 24 h in serum-free condition, then stimulated with 10% FCS for 1 h followed by immunostaining with phalloidin (red) and paxillin mAb (green). A representative view was chosen for photographyBack to article page